Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort

Molecular and Cellular Proteomics

Volumn 12, Issue 6, 2013, Pages 1621-1631

  Azad, Nilofer ^a,b   Yu, Minshu ^a   Davidson, Ben ^c,d   Choyke, Peter ^e   Chen, Clara C ^e   Wood, Bradford J ^e   Venkatesan, Aradhana ^e   Henning, Ryan ^a   Calvo, Kathy ^f   Minasian, Lori ^a   Edelman, Daniel C ^f   Meltzer, Paul ^f   Steinberg, Seth M ^f   Annunziata, Christina M ^a   Kohn, Elise C ^a  

^a John's Hopkins Kimmel Cancer Center   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CASPASE 3; CD31 ANTIGEN; CYCLINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; KI 67 ANTIGEN; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; SORAFENIB; VASCULOTROPIN RECEPTOR 2;

ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD VESSEL PERMEABILITY; CAPILLARY DENSITY; CELL PROLIFERATION; CLINICAL ARTICLE; COHORT ANALYSIS; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; DISEASE COURSE; ENZYME ACTIVATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MONOTHERAPY; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE SEQUENCE; OVARY CANCER; PERITONEUM CANCER; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; PROTEIN TARGETING; SARCOMA; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE; UTERINE TUBE CARCINOMA;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; COHORT STUDIES; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENITAL NEOPLASMS, FEMALE; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; NIACINAMIDE; NITRIC OXIDE SYNTHASE TYPE III; PHENYLUREA COMPOUNDS; POLY(ADP-RIBOSE) POLYMERASES; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84878714371     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.M112.026427     Document Type: Article

References (34)

1. Wilson, P. M., LaBonte, M. J., and Lenz, H. J. (2013) Assessing the in vivo efficacy of biologic antiangiogenic therapies. Cancer Chemother. Pharmacol. 71, 1-12
2. Chen, H. X. (2004) Expanding the clinical development of bevacizumab. Oncologist 9, 27-35 (Pubitemid 38747845)
3. Heath, V. L., and Bicknell, R. (2009) Anticancer strategies involving the vasculature. Nat. Rev. Clin. Oncol. 6, 395-404
4. Teoh, D. G., and Secord, A. A. (2011) Antiangiogenic therapies in epithelial ovarian cancer. Cancer Control 18, 31-43
5. Kelly, R. J., Sharon, E., and Hassan, R. (2011) Chemotherapy and targeted therapies for unresectable malignant mesothelioma. Lung Cancer 73, 256-263
6. Azad, N. S., Posadas, E. M., Kwitkowski, V. E., Steinberg, S. M., Jain, L., Annunziata, C. M., Minasian, L., Sarosy, G., Kotz, H. L., Premkumar, A., Cao, L., McNally, D., Chow, C., Chen, H. X., Wright, J. J., Figg, W. D., and Kohn, E. C. (2008) Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J. Clin. Oncol. 26, 3709-3714
7. Lee, J. M., Sarosy, G. A., Annunziata, C. M., Azad, N., Minasian, L., Kotz, H., Squires, J., Houston, N., and Kohn, E. C. (2010) Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity. Br. J. Cancer 102, 495-499
8. Lee, J.-M., Han, J. J., Altwerger, G., and Kohn, E. C. (2011) Proteomics and biomarkers in clinical trials for drug development. J. Proteomics 74, 2632-2641
9. McDonald, D. M., and Choyke, P. L. (2003) Imaging of angiogenesis: from microscope to clinic. Nat. Med. 9, 713-725 (Pubitemid 36749220)
10. Turkbey, B., Kobayashi, H., Ogawa, M., Bernardo, M., and Choyke, P. L. (2009) Imaging of tumor angiogenesis: functional or targeted? AJR Am. J. Roentgenol. 193, 304-313
11. Choyke, P. L., Dwyer, A. J., and Knopp, M. V. (2003) Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging. J. Magn. Reson. Imaging 17, 509-520 (Pubitemid 36528666)
12. Kety, S. S. (1951) The theory and applications of the exchange of inert gas at the lungs and tissues. Pharmacol. Rev. 3, 1-41
13. Annunziata, C. M., Walker, A. J., Minasian, L., Yu, M., Kotz, H., Wood, B. J., Calvo, K., Choyke, P., Kimm, D., Steinberg, S. M., and Kohn, E. C. (2010) Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. Clin. Cancer Res. 16, 664-672
14. Winters, M., Dabir, B., Yu, M., and Kohn, E. C. (2007) Constitution and quantity of lysis buffer alters outcome of reverse phase protein microarrays. Proteomics 7, 4066-4068 (Pubitemid 350190278)
15. Kim, G., Davidson, B., Henning, R., Wang, J., Yu, M., Annunziata, C., Hetland, T., and Kohn, E. C. (2012) Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome. Cancer 118, 1543-1553
16. Zurita, A. J., Jonasch, E., Wang, X., Khajavi, M., Yan, S., Du, D. Z., Xu, L., Herynk, M. H., McKee, K. S., Tran, H. T., Logothetis, C. J., Tannir, N. M., and Heymach, J. V. (2012) A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann. Oncol. 23, 46-52
17. Gardner, E. R., Kelly, M., Springman, E., Lee, K. J., Li, H., Moore, W., and Figg, W. D. (2012) Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin-binding agent, alone and in combination with bevacizumab. Invest. New Drugs 30, 90-97
18. Jain, L., Sissung, T. M., Danesi, R., Kohn, E. C., Dahut, W. L., Kummar, S., Venzon, D., Liewehr, D., English, B. C., Baum, C. E., Yarchoan, R., Giaccone, G., Venitz, J., Price, D. K., and Figg, W. D. (2010) Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J. Exp. Clin. Cancer Res. 29, 95
19. Jain, L., Woo, S., Gardner, E. R., Dahut, W. L., Kohn, E. C., Kummar, S., Mould, D. R., Giaccone, G., Yarchoan, R., Venitz, J., and Figg, W. D. (2011) Population pharmacokinetic analysis of sorafenib in patients with solid tumours. Br. J. Clin. Pharmacol. 72, 294-305
20. Peer, C. J., Sissung, T. M., Kim, A., Jain, L., Woo, S., Gardner, E. R., Kirkland, C. T., Troutman, S. M., English, B. C., Richardson, E. D., Federspiel, J., Venzon, D., Dahut, W., Kohn, E., Kummar, S., Yarchoan, R., Giaccone, G., Widemann, B., and Figg, W. D. (2012) Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clin. Cancer Res. 18, 2099-2107
21. Tan, D. S., Thomas, G. V., Garrett, M. D., Banerji, U., de Bono, J. S., Kaye, S. B., and Workman, P. (2009) Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J. 15, 406-420
22. Van den Abbeele, A. D. (2008) The lessons of GIST-PET and PET/CT: a new paradigm for imaging. Oncologist 13, 8-13
23. Bertolini, F., Malavasi, N., Scarabelli, L., Fiocchi, F., Bagni, B., Del Giovane, C., Colucci, G., Gerunda, G. E., Depenni, R., Zironi, S., Fontana, A., Pettorelli, E., Luppi, G., and Conte, P. F. (2011) FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer. Br. J. Cancer 104, 1079-1084
24. 18F]fluorothymidine positron emission tomography: a pilot study. J. Clin. Oncol. 25, 4714-4721 (Pubitemid 350086472)
25. 18F]FDG- PET. Int. J. Radiat. Oncol. Biol. Phys. 82, 299-307
26. Burger, R. A. (2007) Experience with bevacizumab in the management of epithelial ovarian cancer. J. Clin. Oncol. 25, 2902-2908 (Pubitemid 47123154)
27. Cannistra, S. A., Matulonis, U. A., Penson, R. T., Hambleton, J., Dupont, J., Mackey, H., Douglas, J., Burger, R. A., Armstrong, D., Wenham, R., and McGuire, W. (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J. Clin. Oncol. 25, 5180-5186 (Pubitemid 350232248)
28. Bodnar, L., Górnas, M., and Szczylik, C. (2011) Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: A phase II study. Gynecol. Oncol. 123, 33-36
29. Matei, D., Sill, M. W., Lankes, H. A., DeGeest, K., Bristow, R. E., Mutch, D., Yamada, S. D., Cohn, D., Calvert, V., Farley, J., Petricoin, E. F., and Birrer, M. J. (2011) Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. J. Clin. Oncol. 29, 69-75
30. Lambrechts, D., Claes, B., Delmar, P., Reumers, J., Mazzone, M., Yesilyurt, B. T., Devlieger, R., Verslype, C., Tejpar, S., Wildiers, H., de Haas, S., Carmeliet, P., Scherer, S. J., and Van Cutsem, E. (2012) VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol. 13, 724-733
31. Van Cutsem, E., de Haas, S., Kang, Y. K., Ohtsu, A., Tebbutt, N. C., Ming Xu, J., Peng Yong, W., Langer, B., Delmar, P., Scherer, S. J., and Shah, M. A. (2012) Bevacizumab in combination with chemotherapy as firstline therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J. Clin. Oncol. 30, 2119-2127
32. Hegde, P. S., Jubb, A. M., Chen, D., Li, N. F., Meng, Y. G., Bernaards, C., Elliott, R., Scherer, S. J., Chen, D. S. (2013) Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab. Clin Cancer Res. 19, 929-937
33. Bates, D. O., Catalano, P. J., Symonds, K. E., Varey, A. H., Ramani, P., O'Dwyer, P. J., Giantonio, B. J., Meropol, N. J., Benson, A. B., and Harper, S. J. (2012) Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with Bevacizumab. Clin. Cancer Res. 18, 6384-6391
34. Nixon, A. B., Pang, H., Starr, M., Hollis, D., Friedman, P. N., Bertagnolli, M. M., Kindler, H. L., Goldberg, R. M., Venook, A. P., and Hurwitz, H. (2011) Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80303. J. Clin. Oncol. 29, Suppl. (Abstr. 10508)